Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.

Tytuł:
Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.
Autorzy:
Quintanilha JCF; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Hammond K; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Liu Y; Duke University School of Medicine, Duke University, Durham, North Carolina, USA.
Marmorino F; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Borelli B; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Cremolini C; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Nixon AB; Duke University School of Medicine, Duke University, Durham, North Carolina, USA.
Innocenti F; AbbVie, Inc., South San Francisco, California, USA.
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Sep; Vol. 88 (9), pp. 4171-4179. Date of Electronic Publication: 2022 May 02.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: Oxford : Wiley-Blackwell
Original Publication: London, Macmillan Journals Ltd.
MeSH Terms:
Angiogenesis Inhibitors*/adverse effects
Hypertension*/chemically induced
Hypertension*/epidemiology
Vascular Cell Adhesion Molecule-1*/blood
Vascular Endothelial Growth Factor A*/antagonists & inhibitors
Vascular Endothelial Growth Factor A*/blood
Angiopoietin-2/blood ; Humans
References:
FDA AVASTIN® prescribing information. 2021. https://www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed August 24, 2021.
Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol. 2020;11:1956. doi:10.3389/fimmu.2020.01956.
Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. Eur J Cancer Suppl. 2013;11(2):172-191. doi:10.1016/j.ejcsup.2013.07.016.
Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med. 2013;23(4):104-113. doi:10.1016/j.tcm.2012.09.008.
FDA STIVARGA® prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf. Accessed January 3, 2022.
Yin X, Yin Y, Shen C, et al. Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials. Onco Targets Ther. 2018;11:6405-6414. doi:10.2147/OTT.S156760.
Rizzo A, Nannini M, Novelli M, Dalia RA, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Therap Adv Med Oncol. 2020;12:1758835920936932. doi:10.1177/1758835920936932.
Quintanilha JCF, Wang J, Sibley AB, et al. Bevacizumab-induced hypertension and proteinuria: a genome-wide analysis of more than 1,000 patients. Br J Cancer. 2022;126(2):265-274. doi:10.1038/s41416-021-01557-w.
Papachristos A, Sivolapenko GB. Pharmacogenomics, pharmacokinetics and circulating proteins as biomarkers for bevacizumab treatment optimization in patients with cancer: a review. J Person Med. 2020;10(3):79. doi:10.3390/jpm10030079.
De Mattia E, Cecchin E, Guardascione M, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol. 2019;25(29):3870-3896. doi:10.3748/wjg.v25.i29.3870.
Quintanilha JCF, Liu Y, Etheridge AS, et al. Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis. 2022;25(1):47-44. doi:10.1007/s10456-021-09799-1.
Antoniotti C, Marmorino F, Boccaccino A. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. Eur J Cancer. 2022;165:116-124. doi:10.1016/j.ejca.2022.01.025.
Liu Y, Lyu J, Bell Burdett K, et al. Prognostic and predictive biomarkers in patients with metastatic colorectal cancer receiving regorafenib. Mol Cancer Ther. 2020;19(10):2146-2154. doi:10.1158/1535-7163.MCT-20-0249.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005;94:209-231. doi:10.1007/3-7643-7311-3_15.
Kong DH, Kim YK, Kim MR, Jang JH, Lee S. Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int J Mol Sci. 2018;19(4):1057. doi:10.3390/ijms19041057.
Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells. J Biol Chem. 2001;276(10):7614-7620. doi:10.1074/jbc.M009705200.
Lee EU, Oh MJ, Jung JW, et al. The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J Korean Med Sci. 2007;22(1):94-98. doi:10.3346/jkms.2007.22.1.94.
Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001;142(5):878-880. doi:10.1067/mhj.2001.118471.
Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GYH. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol. 2001;87(6):805-807. doi:10.1016/S0002-9149(00)01512-5.
Tsai WC, Li YH, Huang YY, Lin CC, Chao TH, Chen JH. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci. 2005;109(1):39-43. doi:10.1042/CS20040307.
Felmeden DC, Blann AD, Lip GYH. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J. 2003;24(7):586-603. doi:10.1016/S0195-668X(02)00635-8.
Kut C, Mac GF, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97(7):978-985. doi:10.1038/sj.bjc.6603923.
Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002;99(17):11205-11210. doi:10.1073/pnas.172161899.
Contributed Indexing:
Keywords: VCAM-1; VEGF-A; hypertension; regorafenib
Substance Nomenclature:
0 (Angiogenesis Inhibitors)
0 (Angiopoietin-2)
0 (VEGFA protein, human)
0 (Vascular Cell Adhesion Molecule-1)
0 (Vascular Endothelial Growth Factor A)
Entry Date(s):
Date Created: 20220419 Date Completed: 20220819 Latest Revision: 20220912
Update Code:
20240104
DOI:
10.1111/bcp.15356
PMID:
35437784
Czasopismo naukowe
Aims: Hypertension is a common toxicity induced by vascular endothelial growth factor (VEGF) pathway inhibitors. There are no validated markers of hypertension induced by these drugs.
Methods: We previously discovered that cancer patients with lower plasma levels of angiopoietin-2, VCAM-1 and VEGF-A are at high risk of developing severe hypertension when treated with bevacizumab. This study aimed to validate the predictive value of these markers in pretreatment plasma samples of an additional cohort of 101 colorectal cancer patients treated with regorafenib. The levels of angiopoietin-2, VCAM-1 and VEGF-A were measured by enzyme-linked immunosorbent assay (ELISA). The association between proteins and grade ≥2 regorafenib-induced hypertension was performed by calculating the odds ratio (OR) from logistic regression. Using the optimal cut-point of each protein, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for hypertension were estimated.
Results: Lower levels of VCAM-1 (P = .015, OR = 3.11, 95% CI 1.27-8.08) and VEGF-A (P = .007, OR = 3.47, 95% CI 1.40-8.75) were associated with a higher risk of hypertension. Levels of angiopoietin-2 were not associated with hypertension. The multivariable model indicates an independent effect of VCAM-1 (P = .018, OR = 3.18, 95% CI 1.25-8.68) and VEGF-A (P = .008, OR = 3.77, 95% CI 1.44-10.21). The presence of low levels of both VCAM-1 and VEGF-A had an OR of 9.46 (95% CI 3.08-33.26, P = 1.70 × 10 -4 ) for the risk of hypertension (sensitivity of 41.4%, specificity of 93.1%, PPV of 70.6% and NPV of 79.8%).
Conclusions: This study confirmed the value of VCAM-1 and VEGF-A levels in predicting hypertension induced by regorafenib, another VEGF pathway inhibitor.
(© 2022 British Pharmacological Society.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies